RxDoctor Payments Data

Christopher Worlton

Psychiatric/Mental Health · Eugene, ORNPI 1447747977

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 39.0% of the total. Reporting peaked in 2024 at $819 and has fallen 79.3% since, to $170 in 2025. Among psychiatric/mental health clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,203in general payments, 2019–2025

Across 194 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$683
  • Teva Pharmaceuticals USA, Inc.$474
  • Vanda Pharmaceuticals Inc.$148
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$111
  • Alkermes, Inc.$110
  • plus $428 from 9 others

What the payments were for

  • Food & beverage$3,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,203 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.

See all psychiatric/mental health providers in Oregon

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl36$49,957
Lurasidone Hcl29$29,086
Prazosin Hcl40$2,155
Aripiprazole34$1,679
Lamotrigine ErLamotrigine11$1,678
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine25$1,473
Doxepin Hcl38$1,345
Olanzapine24$1,306
Fluvoxamine Maleate24$1,212
Risperidone45$952
Bupropion Hcl SrBupropion Hcl48$757
Bupropion XlBupropion Hcl23$734
Divalproex Sodium ErDivalproex Sodium15$733
Trazodone Hcl69$617
Duloxetine Hcl24$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,248$49,95736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 540 psychiatric/mental health providers in Oregon.

Other psychiatric/mental health in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →